ArticleScientific reports2025
Gut expression of CD71 and co-localisation with Dec-1 associated with high levels of serum SIgA and disease activity in SpA.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spondyloarthritis (SpA) correlates with elevated serum secretory-IgA (sSIgA). Retrotranscytosis, mediated by CD71 and Dectin-1, is linked to high sSIgA levels. This research investigated retrotranscytosis in the gut of SpA patients and its relationship with sSIgA, ileocolonoscopic findings, and activity indices. A cohort of 82 was derived from 180 patients based on selection criteria; 41 consented to DCE colonoscopy assessment. Measurements included CD71, Dec-1, sSIgA, and disease scores. Samples exhibiting apical CD71, Dec-1, or both were analysed for receptor/SIgA interactions. Apical CD71 and Dec-1 were predominantly found in the ileum. Multivariate analyses indicated CD71's association with heightened sSIgA (p = 0.05) and ASDAS-CRP (p = 0.036; OR 1.71; 95% CI 1.00-3.11), Dec-1's correlation with ileal inflammation (p = 0.05; OR 3.06; 95% CI 1.00-10.01), and the CD71/Dec-1 relationship with ileal villi atrophy (p = 0.038; OR 4.24; 95% CI 1.00-18.88). Microscopic evaluations demonstrated interactions between CD71/SIgA but not between CD71/Dec-1 or Dec/SIgA. The localised expression of CD71 and its co-localisation with Dec-1 may contribute to systemic increases in serum SIgA and activity scores in SpA patients. The findings suggest that sSIgA levels may serve as a non-invasive biomarker for gastrointestinal involvement in SpA and that retrotranscytosis could be a key mechanism in the gut-joint axis of SpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.